The neurofibromatoses

Practical Neurology

Volumn 10, Issue 2, 2010, Pages 82-93

  Ferner, Rosalie E ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COGNITIVE DEFECT; GENETICS; HUMAN; NEUROFIBROMATOSIS; PATHOLOGY; REVIEW;

COGNITION DISORDERS; HUMANS; NEUROFIBROMATOSES;

EID: 77953957405     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/jnnp.2010.206532     Document Type: Review

References (40)

1. Von Recklinghausen FD. Uber die multiplen fi brome der haut und ihre Beziehung zu den multiplen neuromen. Berlin: A Hirschwald, 1882.
2. Neurofi bromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575-578.
3. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofi bromatosis 1. J Med Genet 2007;44:81-88.
4. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofi bromatoses. Neurology 2001;56:1433-1443.
5. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofi bromatosis 1-like phenotype. Nat Genet 2007;39:1120-1126.
6. Evans, DG, Howard E, Giblin C et al. Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet A 2010;152A:327-332
7. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofi bromatosis type 1 locus. Cell 1990;62:187-192.
8. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofi bromatosis gene: identifi cation of a large transcript disrupted in three NF1 patients. Science 1990;249:181-186.
9. Daston MM, Scrable H, Nordlund M, et al. The protein product of the neurofi bromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992;8:415-428.
10. Xu GF, O'Connell P, Viskochil D, et al. The neurofi bromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
11. Johannessen CM, Reczek EE, James MF et al. The NF1 tumour suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005;102:8573-8578.
12. De Smet L, Sciot R, Legius E. Multifocal glomus tumours of the fi ngers in two patients with neurofi bromatosis type 1. J Med Genet 2002;39:e45.
13. Kimura M, Kamata Y, Matsumoto K, et al. Electron microscopical study on the tumor of von Recklinghausen's neurofi bromatosis. Acta Pathol Jpn 1974;24:79-91.
14. Sharif S, Moran A, Huson SM, et al. Women with neurofi bromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007;44:481-484.
15. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofi bromatosis. Cancer Res 2002;62:1573-1577.
16. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofi bromatosis 1. J Med Genet 2002;39:311-314.
17. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofi bromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006;24:2570-2575.
18. Ferner RE, Hughes RA, Hall SM, et al. Neurofi bromatous neuropathy in neurofi bromatosis 1 (NF1). J Med Genet 2004;41:837-841.
19. De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003;72:1288-1292.
20. Ferner RE, Golding JF, Smith M, et al. [18F]2-fl uoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofi bromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a longterm clinical study. Ann Oncol 2008;19:390-394.
21. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofi bromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997;48:1121-1127.
22. Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofi bromatosis type 1: a randomized controlled trial. JAMA 2008;300:287-294.
23. Ferner RE, Hughes RA, Johnson MR. Neurofi bromatosis 1 and multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;58:582-585.
24. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofi bromatosis-1: controversies and recommendations. Ann Neurol 2007;61:189-198.
25. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofi bromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006;30:90-96.
26. Schindeler A, Little DG. Recent insights into bone development, homeostasis, and repair in type 1 neurofi bromatosis (NF1). Bone 2008;42:616-622.
27. Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofi bromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002;4:105-111.
28. Wishart JH. Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J 1822;18; 393-397.
29. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofi bromatosis 2: a consensus conference statement. Br J Neurosurg 2005;19:5-12.
30. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofi bromatosis 2. Neurology 2002;59:1759-1765.
31. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005;64:1838-1845.
32. Hadfield KD, Newman WG, Bowers NL et al. Germline mutation of INI/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007;80:805-810.
33. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofi bromatosis 2 tumor suppressor. Cell 1993;72:791-800.
34. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membraneorganizing protein causes neuro-fi bromatosis type 2. Nature 1993;363:515-521.
35. Kanowitz SJ, Shapiro WH, Golfinos JG, et al. Auditory brainstem implantation in patients with neurofi bromatosis type 2. Laryngoscope 2004;114:2135-2146.
36. Lustig LR, Yeagle J, Driscoll CL, et al. Cochlear implantation in patients with neurofi bromatosis type 2 and bilateral vestibular schwannoma. Otol Neurotol 2006;27:512-518.
37. Rowe JG, Radatz MW, Walton L, et al. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofi bromatosis. J Neurol Neurosurg Psychiatry 2003;74:1288-1293.
38. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofi bromatosis type 2. N Engl J Med 2009;361:358-367.
39. Sperfeld AD, Hein C, Schröder JM, et al. Occurrence and characterization of peripheral nerve involvement in neurofi bromatosis type 2. Brain 2002;125:996-1004.
40. Trivedi R, Byrne J, Huson SM, et al. Focal amyotrophy in neurofi bromatosis 2. J Neurol Neurosurg Psychiatry 2000;69:257-261.